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Abstract 
T cells engage with antigen-presenting cells to form immunological synapses. These 
intimate contacts are characterized by the complex arrangement of molecules at the 
intercellular interface, which has been described as the supramolecular activation cluster 
(SMAC). However, due to T cells functioning without SMAC formation and the 
difficulties of studying these complex arrangements in vivo, its biological importance has 
been questioned. In light of recent data, we focus this review on the putative functionality 
of SMACs in T-cell synaptic contacts in vivo and emphasize the therapeutic potential of 
SMAC manipulation in immune-driven diseases. 
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Immunological Synapse Formation and SMAC arrangement 
Immunological synapses (IS) are critical intercellular communications between specific 
immune cells and antigen-presenting cells (APC)1. This particular engagement between 
both counterparts requires intimate contact between the aforementioned cells and 
includes multiple factors and complex signaling cascades of activation 1,2. T-cell ISs have 
been largely studied and represent the best-known IS type 3, although ISs may also be 
established by different types of effector cells, such as NK or B cells 4-6. The formation of 
an IS involves the T-cell recognition of specific antigens that are presented by APCs. 
Major Histocompatibility Complexes (MHC) display antigens at the APC cell surface, 
which are detected by T-cell receptor (TCR) molecules that are displayed on the T-cell 
membrane 7. The interaction between the antigen-MHC and the TCR induces the TCR 
signaling cascade 8, thus initiating the activation of the T cell, which is characterized by 
the phosphorylation and polarization of tyrosine kinases such as lymphocyte-specific 
protein tyrosine kinase (Lck) and zeta-chain-associated protein kinase 70 (ZAP-70) at the 
interface 9,10 (Figure 1). In mature IS formation, the process of activation involves severe 
changes to the micro-anatomical configuration of the T cell that are characterized by 
rearrangement of the actin cytoskeleton and are driven by the microtubules organizer 
center (MTOC), which becomes polarized toward the APC and participates in the 
organization of secretory domains 11-14. The polarization of the T cell is also accompanied 
by the rearrangement of lymphocyte function-associated antigen 1 (LFA-1) molecules 
that segregate three-dimensionally at the IS interface and specifically bind to the APC’s 
intercellular adhesion molecule 1 (ICAM-1) 15,16. This binding of LFA-1/ICAM-1 takes 
place at the interface, and LFA-1/ICAM-1 complexes rearrange micro-anatomically, 
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forming a ring-shaped area named the peripheral supramolecular activation cluster 
(pSMAC), which surrounds a characteristic central accumulation of TCRs, known as the 
central supramolecular activation cluster (cSMAC) 15 (Figure 1 and Box). This way, a 
“bull’s eye” characteristic structure is formed, where an outer ring contains the adhesion 
molecules, and an inner area contains the signaling molecules. In cytolytic T cells, the 
cSMAC may also contain secretory domains that usually encompass an area of smaller 
size and is located near the TCR signaling central cluster, where lytic granules of effector 
molecules are concentrated and released 6,17,18. Importantly, LFA-1 molecules are linked 
to talin proteins, which are key integrins involved in cell migration and cellular junction 
because they are linked to the actin-myosin cytoskeleton through vinculin 15,19,20.  
 
Visualization of SMACs in vivo 
The initial description and most of the studies on the microanatomy and function of ISs 
have been performed in vitro 1,15,21. Although the knowledge on ISs has substantially 
grown and successfully improved based on in vitro experiments, the functionality of ISs 
in living organisms has barely been explored. A criticism often rises considering that in 
vitro environments are different from those in tissue. Cultures and planar bilayers are 
isolated, two-dimensional milieus, whereas tissues are three-dimensional environments in 
which cells receive information and signals from different planes and directions 
involving diverse biological systems. Thus, research of ISs in vivo is an important matter 
for a complete understanding of T-cell biology. 
Formation of SMAC in vivo has been demonstrated using high-resolution 
confocal microscopy of labeled, fixed tissue with multiple fluorescence-specific 
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antibodies. The formation of the CD3/TCR central cluster (cSMAC) and/or the peripheral 
segregation of LFA-1 (pSMAC) are observed in different tissues, such as the brain and 
secondary lymphoid tissues 22,23. ISs are stable and preserved structures in mammals. As 
described in vitro, ISs show a flat interface in vivo; and cSMAC and pSMAC are formed 
in all species studied so far. From rodents 22 to primates 24, including humans 25, the 
formation of SMAC seems to be consistently involved in mammalian immune responses. 
However, despite the good level of resolution, this in vivo technique has the 
limitation of picturing static events. High-resolution confocal images in fixed tissue 
represent a scenery taken at a certain and specific moment and do not resolve the 
dynamics of the IS. Two-photon microscopy in living animals will be the ideal technical 
approach to show the dynamics of IS formation in vivo, but some issues must still be 
solved. Currently, multi-photon microscopes are able to image several hundreds of 
microns deep into tissue; however, the resolution of the anatomical details is still not 
sufficient to distinguish the micro-anatomy of the IS at the SMAC level. In addition, 
observations are hampered by the parenchyma’s high auto-fluorescence and by the 
reduced number of fluorophores that are available to detect molecule arrangements in 
vivo in time-lapse, live imaging. Two-photon microscopy studies in tissue, especially in 
lymph nodes, have shown the dynamics by which T cells engage APCs (i.e., dendritic 
cells), but no micro-anatomical details of the SMAC were given 26,27. Currently, time-
lapse studies of the microanatomy of complete SMAC formation, containing the central 
and peripheral clusters, have not been yet performed in living tissue. Notably, however, a 
successful attempt was performed regarding visualization of the dynamics of the 
formation of the TCR central cluster using a two-photon microscope in lymph nodes in 
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live mice. In a study by Friedman et al., some features of the TCR dynamics in vivo, as 
well as the behavior of TCR accumulation, were revealed 28. In addition Azar et al., using 
linker for activation of T cells (LAT)-EGFP labeled T cells, were able to detect the in 
vivo formation of central and peripheral clusters of LAT at the IS interface in lymph 
nodes, which may underlie some insights into the molecular distribution of SMACs 29. 
The next scientific challenge is the combination of different fluorophores to observe the 
dynamics of the peripheral SMAC in relation to the central TCR cluster and how the 
formation of these structures affects immune responses in healthy subjects and 
experimental models of diseases. 
 
Function of SMAC in vivo 
Previous observations have shown that SMAC formation is not required for TCR 
signaling or for the effectiveness of cytotoxic T cells 6,30. These results question the 
biological importance of SMAC formation. Why is such an enormous and complex 
arrangement in the cell needed? Why invest such a large amount of energy and effort? 
pSMAC and cSMAC formations were first observed in brain tissue, in the context of the 
clearance of virus-infected cells 22. In this case, the formation of SMACs preceded the 
elimination of viral-infected cells in immune-competent animals that were primed with 
an adaptive immune response 22. In this context, the percentage of ISs forming SMACs 
and engaged with virus-infected cells was approximately 60% in a specific time window, 
before complete viral clearance 31,32. These results indicate that a large percentage of 
SMAC formation may be essential for viral clearance in tissue, suggesting its biological 
significance 31. In the same scenario of viral clearance, the secretory domain that was 
 7
observed at the immunological synaptic interface was characterized by the formation of 
interferon-gamma (IFN-Ȗ) and perforin clusters, which conveys that both effector 
molecules and their polarization at the synaptic interface may be necessary phenomena 
for the elimination of virus-infected cells 31. In fact, IFN-Ȗ- or perforin-deficient mice are 
unable to eliminate virus-infected cells from the brain 33. However, whether completely 
mature SMAC rearrangements will take place at the interface seems to depend upon 
multiple factors. For example, IFN-Ȗ appears polarized in Kupfer type (with SMAC) and 
non-Kupfer type (without SMAC) synapses 31, which indicates that the formation of 
mature synapses with SMAC does not precede the formation of the secretory domain; 
therefore, SMAC formation may not be strictly necessary for the release of effector 
molecules and elimination of target cells. In fact, although cytotoxic ISs restrict killing to 
antigenic target cells, IFN-Ȗ signaling is also detected in non-antigenic bystander cells 34, 
suggesting a certain leakage or multidirectional diffusion of the cytokine, which implies 
defective SMAC formation. 
On the other hand, secretory effector molecules have a different pattern of 
segregation that is independent of c- and pSMAC formation. Therefore, different 
cytokines show different patterns of secretion in T cells. For example, IFN-Ȗ and 
interleukin 2 (IL-2) are polarized and secreted to the synaptic interface, while TNF-Į and 
chemokine (C-C motif) ligand 3 (CCL3) are secreted multi-directionally 35. These 
established patterns of secretion indicate a different behavior of T-cells that depends on 
the context of the immune response. Thus, the need for complex SMAC rearrangement 
may not always be required.  
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These results indicate that SMAC arrangement could be necessary to directionally 
secrete specific molecules towards the APC without altering adjacent cells, thus safely 
channeling intercellular communication 13,36 (Figure 2). Outer ring LFA-1/ICAM-1 
adhesion allows for the formation of a shielded micro-chamber, which is an intercellular 
space that is kept isolated from the surrounding environment. This flat interface feature is 
possible due to rearrangement of the actin cytoskeleton, which forms a consistent and 
renewable scaffold that is oriented to the interface 37,38. Most likely, the reason for these 
interface arrangements may be for maximal reduction of the surface at the intercellular 
contact, which could result in more effective communication and less chance of 
membrane and receptor miss-folding. In that intercellular space, cytotoxic compounds, 
such as effector molecules, can be safely delivered, and signaling only occurs with the 
contacting cell, without damaging the surrounding healthy cells that are not involved in 
the immunological response. Therefore, the formation of SMACs may represent a highly 
evolved and specific immune response that only has an effect on target cells and does not 
affect bystander cells. Thus, it can be hypothesized that the SMAC is a necessary 
structure to channel cytokines and other effector molecules in an extremely selective 
manner (Figure 2). 
Overall, T-cell synaptic contacts may be necessary for an effective immune 
response, but, the formation of SMACs may depend on the immunological context and 
the effector molecules that are delivered. It is, therefore, tempting to speculate that the 
ideal situation may be SMAC formation because it would preserve the surrounding tissue 
and result in a more specific and safe response. As a drawback, an immune response with 
SMAC formation is most likely slower and requires high-energy waste. Thus, if the 
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immune response needs to be faster and inexpensive, it should be carried out without 
SMAC. 
 In summary, in vivo studies of Kupfer-type ISs exhibit a complex scenario for 
further research. Multiple types of intercellular combinations, involving diverse cytokine 
release and adaptable immune responses within different tissues, are important variables 
that should be considered for future research, although the visualization and unraveling of 
the IS function will only be fully achieved in vivo if new, specific approaches are 
designed that selectively inhibit IS formation in the tissue of a living organism. 
 
A therapeutic view of the immunological synapse 
Because the formation of the SMAC may be an important part of the specificity and 
effectiveness of the T-cell response, manipulation of ISs represents a promising tool from 
a therapeutic point of view. It presents an advantage whereby we could specifically 
inhibit or activate the different immune responses according to therapeutic needs, as 
multiple targets could potentially be aimed to hinder or empower IS formation. In fact, 
immunotherapy is a therapeutic field that has lately been developed and is becoming 
promising, particularly for cancer. Specific drugs, usually artificially made antibodies, 
have been designed to empower anti-tumor immunity, and most of them intervene at the 
synaptic level (Figure 3). 
One of the most hopeful approaches to directly stimulate the formation of specific 
ISs between T and tumor cells is the development of bi-specific T-cell engager (BiTE) 
antibodies. These monoclonal antibodies target the TCR/CD3 complex and tumor 
antigens, such as CD19, epithelial cell adhesion molecule (EpCAM) or epidermal growth 
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factor receptor (EGFR). This way, the antibodies promote the synaptic interaction 
between tumor cells and T cells and induce the activation of cytolytic T cells. This 
engagement-induced tumor-cell death leads to T-cell accumulation in the tumor 
microenvironment and reduces tumor cell proliferation in vivo 39.  
Another successful approach to modify synaptic contacts is based on the 
development of antibodies that are able to antagonize receptors that inhibit the immune 
response. A successful case is that of ipilimumab, an antibody that binds an inhibitory T-
cell protein called cytotoxic T lymphocyte antigen 4 (CTLA-4). CTLA-4 is expressed in 
activated T cells and is recruited to the cSMAC in competition with the T-cell activation 
molecule, CD28 40,41. The binding of ipilimumab interferes with CTLA-4-mediated T-cell 
suppression at the cSMAC, therefore, facilitating active synaptic interactions between T 
cells and target cells, which results in a more aggressive immune response against the 
tumor. Ipilimumab has been tested in patients with melanoma (Yervoy®), and it has been 
proven to be effective in specific cases because it removes melanoma without tumor 
recurrence 42-44. Analogously, therapeutic blockade of programmed cell death 1 (PD-1), 
which is also localized at the cSMAC, increases T-cell motility and cytotoxic 
effectiveness, thus improving viral clearance 45. Indeed, the combination of both, CTLA-
4 and PD-1 blockade, has been proven to be effective toward tumors by increasing the 
cytolytic T-cell population and reducing regulatory T cells 46. 
In this context, optimization of the cytolytic arm seems to be the primary therapeutic 
strategy to eliminate tumors because the tumorigenic microenvironment facilitates a pro-
inflammatory response that promotes tumor growth. In the case of CNS tumors, 
particularly in human glioma, the formation of SMAC has been studied in depth. In 
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glioma tissue, mature ISs are established between T-cells and tumorigenic cells, although 
at a low rate 25. However, SMAC analyses performed in murine experimental models of 
glioma have shown that the formation of Kupfer-type synapses does not predict the 
elimination of the tumor 47, which is different from the process of viral clearance 31. This 
feature may be characteristic of tumors because the multidirectional delivery of cytotoxic 
compounds could theoretically be the fastest and most effective way to destroy tumors in 
an environment where the majority of bystander cells should be rapidly eliminated. 
However, because T cells form SMACs, they may still be needed in a sufficient quantity 
for the recognition of specific antigens to take place. This fact supports the idea that 
SMACs would only be formed when the tissue in the vicinity must be preserved. These 
concepts may open new avenues of research regarding the formation of SMAC or 
bonafide ISs. 
On the other hand, tumor development and other immune-mediated degenerative 
diseases might be a consequence of defective SMAC formation. This alteration may be 
reflected in altered immune responses due to deficient recognition of the antigen, anergy 
or exhaustion of the T-cell response, either of the regulatory or cytolytic response. In line 
with this, a recent study showed for the first time that alterations in SMAC formation in T 
cells can be a crucial element in immune disorders. In this report, CD4 T cells obtained 
from patients with multiple sclerosis and type-1 diabetes were exposed to antigens from 
influenza virus. Both CD4-T-cell groups showed divergent formation of SMAC when 
compared with normal T cells obtained from healthy patients 48. These differences 
included deficient SMAC-structure formation regarding the proper CD3/TCR or MHC 
accumulation and ICAM-1/LFA-1 segregation, a distinct motility of T cells, and altered 
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timing and velocity of SMAC formation. Importantly, a deficiency in SMAC formation 
sets the possibility for alteration in cellular communication and could explain how T cells 
might escape the negative selection that takes place in autoimmune diseases. 
Another example regarding the X-linked lymphoproliferative syndrome, which is 
characterized by fatal responses to Epstein-Barr virus infection, has recently been 
reported. This syndrome is caused by mutations affecting the adaptor SAP (signaling 
lymphocytic activation molecule (SLAM)-associated membrane protein), which is a 
molecule involved in correct arrangement of the synaptic contact. In fact, SAP-deficient 
cytotoxic T lymphocytes exhibit abnormal actin organization and reduced centrosome 
docking at T-cell–B-cell ISs 49. These results demonstrate that correct assembling of T 
cells with their target cells and the micro-anatomical arrangement of SMACs and their 
associated organelles is a fundamental process in the immune response. 
We are beginning to understand how malfunction of SMAC formation may induce 
different immune-mediated diseases. The understanding of this process in vivo as well as 
the specific mechanisms occurring during SMAC formation in tissues within different 
immune scenarios will be crucial to propose molecular targets that restore the correct 
arrangement of Kupfer-type ISs. 
 
Box 
The term immunological synapse has been used to generally define communications 
between immune cells, although it is also specifically and more accurately referred to as 
the formation of the characteristic interface with complex rearrangements of molecules 
and compounds called SMAC (Supra-Molecular Activation Cluster). Synapses that form 
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SMACs are considered mature immunological synapses and, in some publications, to 
honor its discoverer, immunological synapses are classified as Kupfer-type or non-
Kupfer-type immunological synapses according to the presence or absence of the “bull’s 





Figure 1. T-cell immunological synapse forming a SMAC (Kupfer-type). T cells 
recognize antigens that are presented by the MHC of an APC through the TCR/CD3 
complex. Then, T cells are activated through phosphorylation of tyrosine kinases such as 
Lck and ZAP-70, which are polarized to the T-cell/APC interface. This activation leads 
to dramatic changes in the cell, including the rearrangement of adhesion molecules, such 
as LFA-1, which are segregated towards the interface to bind ICAM-1 of the APC and 
form the peripheral activation cluster (pSMAC). On the other hand, TCR/CD3 molecules 
are aggregated at the center of the interface and form the central SMAC (cSMAC). In 
addition, cytotoxic granules are delivered to the center of the interface and form the 
secretory domain. 
 
Figure 2. Hypothetical strategies for cytolytic T-cell responses in tissue. A. 
Unidirectional secretion of effector molecules after immunological synapse formation. T 
cells (red) form mature immunological synapses after antigen recognition and subsequent 
apposition to an APC (blue). LFA-1 adhesion molecules are segregated at the external 
border of the interface (red), forming the pSMAC, whereas TCR (green) is concentrated 
at the center of the interface, forming the cSMAC, where the cytolytic granules (yellow 
arrow) may be delivered in one specific direction. With this strategy, the APC (blue) can 
be specifically eliminated without damaging bystander cells (light brown cells). B. 
Multidirectional secretion of effector molecules without bona fide synapse formation. T 
cells (red) may not form mature immunological synapses after antigen recognition; thus, 
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the strict apposition to antigen-presenting cells (blue) may not be necessary. LFA-1 
molecules (red) do not arrange as pSMAC, and TCR does not concentrate at the center of 
the interface, forming the cSMAC. Cytolytic granules (yellow arrows) may be delivered 
multi-directionally. With this strategy, bystander APCs (blue) can be eliminated 
discretionally. 
 
Figure 3. Therapeutic targets at the immunological synapse. CTLA-4 competes with 
CD28 for CD80/CD86. Bound CTLA4-CD80/CD86 complexes are recruited to the 
cSMAC, whereas unbound CD28 is segregated to the pSMAC. PD1 molecules bind to 
PDL1 and are recruited to the cSMAC. The binding of CTLA4-CD80/CD86 inhibits T-
cell activation. Thus, CTLA-4 blocking antibodies hamper binding to CD80/CD86, 
which facilitates the binding of CD80/CD86 with CD28 and impedes CTL inhibition. 
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